Global Autoimmune Disease Diagnostics Market Size, Share, Forecast Report, 2020-2027

Global Autoimmune Disease Diagnostics Market accounted for USD 3300 million and expected to register 7.6% CAGR during the forecast period (2018–2023)

Immune system provides protection to human body by reacting to foreign particles and germs like bacteria and viruses. Sometimes human immune system fails to differentiate between own cells and foreign objects and starts attacking own cells, this medical condition is called autoimmune diseases. The increasing prevalence of autoimmune diseases, increasing healthcare expenditure, and growing awareness autoimmune diseases are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as mergers and acquisitions and new product launches are contributing to the growth of the market. For instance, in October 2017, Abbott acquired Alere Inc. for USD 5300 million, with this deal Abbott will gain control over USD 7000 million diagnostics sales of Alere Inc. and strengthen its position in global autoimmune disease diagnostics market.

The increasing false positive results, and price war between companies may hamper the growth of the market during the assessment period.

Key Players:

Some of the key players in the global autoimmune disease diagnostics market are Siemens Healthcare Private Limited, bioMérieux SA, Bio-rad Laboratories, Beckman Coulter, Inc., AstraZeneca, EUROIMMUN AG, F. Hoffmann-la Roche, Inova Diagnostics, Inc.,Myriad Genetics, Inc., Thermo Fisher Scientific, Trinity Biotech Plc., and Hemagen Diagnostics, Inc.

Segmentation:

The global autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.

On the basis of disease type, the market has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further divided into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been classified into inflammatory bowel disease, thyroid, type 1 diabetes, and others.

The test type segment has been divided into western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.

The market, by end-user, has been segmented into hospitals, diagnostics centers, research laboratories, and others.

Global Autoimmune Disease Diagnostics Market, by Disease Type

 Systemic Autoimmune Disease

• Psoriasis
• Multiple Sclerosis
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Others

Localized Autoimmune Disease

• Inflammatory Bowel Disease
• Type 1 Diabetes
• Thyroid
• Others

Global Autoimmune Disease Diagnostics Market, by Test Type

• Western Blotting
• Enzyme-linked Immunosorbent Assay (ELISA)
• Double Immune Diffusion
• Dot Blot
• Counter Immune-electrophoresis
• Line Blot
• Immunofluorescence assays (IFA)
• Multiplex Immunoassay
• Agglutination
• Others

Global Autoimmune Disease Diagnostics Market, by End-User

• Hospitals
• Diagnostics Centers
• Research Laboratories
• Others

Global Autoimmune Disease Diagnostics Market, by Region

Americas North America

• US
• Canada

• South America

Europe Western Europe

• Germany
• France
• Italy
• Spain
• UK
• Rest of Western Europe

Eastern Europe Asia-Pacific

• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Middle East & Africa

• Middle East
• Africa

Company Profiles    

• Siemens Healthcare Private Limited
• bioMérieux SA
• Bio-rad Laboratories
• Beckman Coulter, Inc.
• AstraZeneca
• EUROIMMUN AG
• Hoffmann-la Roche
• Inova Diagnostics, Inc.
• Myriad Genetics, Inc.
• Thermo Fisher Scientific
• Trinity Biotech Plc.
• Hemagen Diagnostics, Inc.